Co-Diagnostics Reports Second Quarter 2026 Financial Results
Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue was $0.17M vs $0.16M a year earlier. Operating loss was $6.2M, net loss $6.3M ($1.46/share). Cash was $3.6M. The company said it completed studies and submitted a 510(k) for its Flu A/B and RSV multiplex test, and raised $3.0M via private placement.
How this was made
The 30-second read
Why it matters
Near-term trading focus is on regulatory progress for the Flu A/B & RSV multiplex test (510(k) plus CLIA waiver by application) and the company’s ability to fund ongoing clinical and manufacturing expansion after the $3.0M private placement.
Market read
This is a company-specific earnings and regulatory update with a concrete FDA filing milestone and a small capital raise, likely to drive sentiment and risk pricing more than fundamentals alone.
What to watch
The $3.0M private placement can be dilutive, and the article does not provide guidance or clearance timelines, limiting how far traders can extrapolate from the 510(k) filing alone.
Background
Co-Diagnostics is advancing an integrated molecular diagnostics ecosystem (instrumentation, assays, cloud connectivity, and AI-enabled capabilities) toward commercialization.
Ticker impact
Co-Diagnostics reports Q2 results and a new FDA 510(k) submission for its Co-Dx PCR Flu A/B & RSV test on the Co-Dx PCR Pro instrument.
Bias toward near-term upside as traders price in regulatory progress, but dilution and small cash balance can cap the move.
The article discloses specific regulatory actions (510(k) plus CLIA waiver by application) and provides financial datapoints plus a fresh capital raise, which together can drive sentiment and risk repricing.
Market effects
Supports the broader molecular diagnostics theme that point-of-care multiplex platforms are moving through FDA pathways.
Highlights MENA localization efforts via Saudi manufacturing site approval and lease execution, which may influence regional distributor expectations.
Continues global health diagnostics development (TB, Ebola, Bundibugyo) and could affect partner/distributor appetite for emerging outbreak testing kits.
Counterpoint
Regulatory submission is not clearance, and the company still reports operating losses and low cash, so the market may discount the milestone until FDA feedback or clearance arrives.
Key entities
- companyCo-Diagnostics, Inc.
Reports Q2 2026 financial results, a new FDA 510(k) submission for its Co-Dx PCR Pro multiplex test, and a $3.0M private placement.
- productCo-Dx PCR Pro instrument
The platform on which the Flu A/B & RSV upper respiratory multiplex test is being submitted for FDA 510(k) clearance with a concurrent CLIA waiver by application.
- executiveWes Lindsey, Ph.D., MBA
Appointed Chief Scientific Officer to lead scientific and regulatory strategy and pipeline expansion.
